Drug Trial Radar · NCT06679062
Suvorexant for Treatment of AUD and PTSD
Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
76
Planned (sponsor's estimate)
Start
Jul 16, 2025
Primary completion
Mar 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Pharmacotherapies for Alcohol and Substance Use Disorders AllianceAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of California, Los Angeles; The University of Texas Health Science Center, Houston
- First posted
- Nov 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to determine if suvorexant (SUV) will reduce insomnia in 76 men and women veteran and non-veterans between the ages 21-65 with posttraumatic stress disorder (PTSD) symptoms and alcohol use disorder (AUD). All participants will have a 7-day placebo run-in period, followed by a random assignment to receive placebo or suvorexant for an additonal 14 days. Post-randomization, participants will attempt to stop drinking for two weeks and will complete daily virtual diaries and study outcome assessments via in-person clinic visits on days 7 and 14.
Conditions
- Alcohol Use Disorder (AUD)
- Post Traumatic Stress Disorder (PTSD)
- Insomnia
Interventions
SuvorexantDrug
Suvorexant is described chemically as: \[(7R)-4-(5-chloro-2-benzoxazolyl) hexahydro-7-methyl-1H-1,4-diazepin-1-yl\]\[5-methyl-2-(2H-1,2,3-triazol2-yl)phenyl\]methanone. SUV's empirical formula is C23H23ClN6O2 and the molecular weight is 450.92. Each film coated tablet contains 10mg or 20mg of suvorexant.
PlaceboOther
Film coated tablet to match the active drug.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Insomnia Severity Index (ISI) score from baseline to Day 14.Time frame: Baseline (Day 0) and Day 14
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University of California - Los Angeles
Los Angeles, California · Terminated
The University of Texas Health Science Center - Houston
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.